Vical Says Vaxfectin Can Be Used in Influenza Vaccine
Posted on: Friday, 12 October 2007, 06:00 CDT
Biopharmaceutical company Vical has said that data from a study in mice has demonstrated the potential of its patented Vaxfectin adjuvant to be used as a dose-sparing agent with a pandemic influenza vaccine currently stockpiled by the US government.
The dose-sparing ability could be critical in extending limited vaccine supplies to protect a great number of people in the event of a pandemic influenza outbreak, according to the company.
In the study, mice were vaccinated with US government-supplied H5N1 vaccine, with or without the Vaxfectin adjuvant, and evaluated for antibody responses by enzyme-linked immunosorbent assay (ELISA). After a single injection, the Vaxfectin-formulated vaccine yielded five-fold higher antibody responses at the same dose as the unformulated vaccine, and comparable or better antibody responses at one-third the dose of unformulated vaccine.
After a second injection, the Vaxfectin-formulated vaccine yielded nine-fold higher antibody responses at the same dose as the unformulated vaccine, and five-fold better antibody responses at one-third the dose of the unformulated vaccine.
Alain Rolland, senior vice president of product development, Vical, said: "We continue to expand the database demonstrating the dose-sparing and immunogenicity-enhancing capabilities of our Vaxfectin adjuvant, as well as its potential safety and tolerability advantages. Our lead DNA vaccine candidate against H5N1 influenza, formulated with Vaxfectin, provided 100% protection in mice and ferrets against lethal challenges, and is currently in Phase I human testing. We are encouraged by the recent influenza and measles data, and look forward to further evaluation of Vaxfectin."
Source: Datamonitor
Related Articles
- High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older
- Nabi Biopharmaceuticals Announces Positive Interim Results of NicVAX Immunogenicity Study; Revised Schedule Significantly Increases Antibody Response in Vast Majority of Subjects
- Novartis Menveo(R) Vaccine Shows Superior Immune Response Against Four Types of Meningitis Disease in Pivotal Phase III Trial
- Vical Demonstrates Dose-Sparing of Protein-Based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
- Vical's Vaxfectin(TM) Adjuvant With Needle-Free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
- Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
- Vical Vaccine Adjuvant Boosts Immune Response to Influenza Vaccine
- Higher Antibody Responses Observed in Young Children Receiving MedImmune's Investigational Intranasal Influenza Vaccine Compared to Injectable Vaccine
- Vical's DNA Vaccine With Vaxfectin(TM) Adjuvant Advances in Pandemic Influenza Program
- Thai Gov't to Vaccinate 150,000 Workers Against Influenza
 |
 |
User Comments (0)
RSS Feeds